Abstract
Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Lung Diseases, Interstitial / complications
-
Lung Diseases, Interstitial / drug therapy*
-
Randomized Controlled Trials as Topic
-
Rituximab
-
Scleroderma, Systemic / complications
-
Scleroderma, Systemic / drug therapy*
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Immunologic Factors
-
Rituximab